Please find attached herewith the Annual Secretarial Compliance Report for the Financial Year ended 31st March, 2025
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2025, as mandated under SEBI's Listing Regulations. The report, issued by practicing company secretaries Samdani Shah & Kabra and dated May 13, 2025, covers compliance with SEBI Act, Securities Contracts Regulation Act, and various SEBI regulations including LODR, Insider Trading, and Takeover norms. Annexure I records NIL deviations or non-compliances during the review period. Annexure III confirms full compliance on all 13 checks — secretarial standards, board policies, website disclosures, director eligibility, related-party transactions, insider trading, and timely event disclosures. No prior-year observations needed remedial action, and no enforcement action was taken by SEBI or stock exchanges against the company.
This is a routine annual compliance filing with a clean record — no penalties, no non-compliance, and no regulatory action. A spotless report mildly reinforces governance credibility but is unlikely to materially move the stock price on its own.